Taking the Guesswork Out of Stopping TKIs.
More and more patients with chronic myeloid leukemia are discontinuing therapy after their cancer goes into remission, improving their quality of life and remaining disease-free for years. However, this strategy works only in a subset of patients. Researchers are attempting to refine criteria for discontinuing treatment, determine the manner in which therapy should be stopped, and identify prognostic biomarkers.